美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Ophthotech Corporation

1.39

0.0000

成交量：- -

成交额：- -

市值：5,757.60万

市盈率：0.82

高：1.39

开：1.39

低：1.39

收：1.39

数据加载中...

总览公司新闻公告

公司资料

公司名字：

Ophthotech Corporation

交易所：

NASDAQ

成立时间：

- -

员工人数：

- -

公司地址：

- -

官网：

http://www.ophthotech.com

邮编：

- -

电话：

- -

传真：

- -

简介：

Ophthotech Corporation成立于2007年1月5日，在美国特拉华州。公司是一家生物制药公司，专门从事新型疗法的发展，治疗眼睛的背部疾病，重点开发治疗年龄相关性黄斑变性，或AMD。公司的最先进产品的候选是Fovista，这是在第3阶段的临床开发组合使用与代表保健为湿性AMD的治疗的目前标准的抗VEGF药物。公司已完成了第一阶段1和一个2b期Fovista的组合给予的抗VEGF药物Lucentis的临床试验。公司也正在开发其候选产品Zimura，对于患者的地理萎缩，干性AMD的一种形式的治疗，结合抗VEGF疗法用于治疗息肉状脉络膜血管病变，湿性AMD的特定类型，患者谁不与抗-VEGF单一疗法充分应对处理或为其抗-VEGF单一疗法失败，并且，潜在地，在用抗VEGF治疗和Fovista对于抗VEGF抗性湿性AMD的患者的治疗中谁被认为具有补体结合介导的炎症。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/OPHT/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OPHT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OPHT\",,,,,undefined,":{"symbol":"OPHT","market":"US","secType":"STK","nameCN":"Ophthotech Corporation","latestPrice":1.39,"timestamp":1567195200000,"preClose":1.39,"halted":0,"volume":0,"delay":0,"floatShares":26608262,"shares":41421548,"eps":1.7,"marketStatus":"盘后交易","change":0,"latestTime":"05-21 17:46:00 EDT","open":1.39,"high":1.39,"low":1.39,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.7,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1747872000000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.39,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OPHT\",,,,,undefined,":{"symbol":"OPHT","floatShares":26608262,"roa":"--","roe":"--","lyrEps":1.702247,"shares":41421548,"dividePrice":0,"high":1.39,"amplitude":0,"preClose":1.39,"low":1.39,"week52Low":1.02,"pbRate":"0.46","week52High":4.5,"institutionHeld":0,"latestPrice":1.39,"eps":1.7,"divideRate":0,"volume":0,"delay":0,"ttmEps":1.7,"open":1.39,"prevYearClose":1.39},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.ophthotech.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0102},{"period":"1month","weight":0.1262},{"period":"3month","weight":-0.0328},{"period":"6month","weight":-0.0014},{"period":"1year","weight":0.1185},{"period":"ytd","weight":0.0116}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Ophthotech Corporation成立于2007年1月5日，在美国特拉华州。 公司是一家生物制药公司，专门从事新型疗法的发展，治疗眼睛的背部疾病，重点开发治疗年龄相关性黄斑变性，或AMD。 公司的最先进产品的候选是Fovista，这是在第3阶段的临床开发组合使用与代表保健为湿性AMD的治疗的目前标准的抗VEGF药物。公司已完成了第一阶段1和一个2b期Fovista的组合给予的抗VEGF药物Lucentis的临床试验。公司也正在开发其候选产品Zimura，对于患者的地理萎缩，干性AMD的一种形式的治疗，结合抗VEGF疗法用于治疗息肉状脉络膜血管病变，湿性AMD的特定类型，患者谁不与抗-VEGF单一疗法充分应对处理或为其抗-VEGF单一疗法失败，并且，潜在地，在用抗VEGF治疗和Fovista对于抗VEGF抗性湿性AMD的患者的治疗中谁被认为具有补体结合介导的炎症。","exchange":"NASDAQ","name":"Ophthotech Corporation","nameEN":"Ophthotech"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"OPHT\",market:\"US\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OPHT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-02-26","symbol":"OPHT","fiscalQuarterEnding":"2018/12","expectedEps":-0.36,"name":null,"time":"盘前","type":"earning","dateTimestamp":1551157200000,"reportTimeType":"pre","actualEps":-0.53},{"market":"US","date":"2018-10-31","symbol":"OPHT","fiscalQuarterEnding":"2018/09","expectedEps":-0.43,"name":null,"time":"盘前","type":"earning","dateTimestamp":1540958400000,"reportTimeType":"pre","actualEps":-0.41},{"market":"US","date":"2018-08-01","symbol":"OPHT","fiscalQuarterEnding":"2018/06","expectedEps":-0.4,"name":null,"time":"盘前","type":"earning","dateTimestamp":1533096000000,"reportTimeType":"pre","actualEps":-0.37},{"market":"US","date":"2018-05-09","symbol":"OPHT","fiscalQuarterEnding":"2018/03","expectedEps":null,"name":null,"time":"盘前","type":"earning","dateTimestamp":1525838400000,"reportTimeType":"pre","actualEps":-0.36},{"market":"US","date":"2018-02-27","symbol":"OPHT","fiscalQuarterEnding":"2017/12","expectedEps":-0.58,"name":null,"time":"盘前","type":"earning","dateTimestamp":1519707600000,"reportTimeType":"pre","actualEps":-0.26}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OPHT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OPHT\",market:\"US\",delay:false,,,undefined,":{}}}